ABCL AbCellera Biologics Inc.
Price Chart
Executive Summary
AbCellera appointed Dr. Victor Sandor as an independent director on June 1, 2026. Dr. Sandor is a seasoned medical oncologist with a track record of securing drug approvals at Array BioPharma (Braftovi/Mektovi) and Incyte (Jakafi). This is a routine board appointment with no material financial impact.
Actionable Insight
Routine board appointment with no immediate trading catalyst. Monitor for any future pipeline or partnership announcements that Sandor's expertise might influence.
Key Facts
- Dr. Victor Sandor appointed as independent director effective June 1, 2026.
- Sandor served as CMO at Array BioPharma (acquired by Pfizer) and SVP at Incyte.
- He will serve until the next annual meeting and is not on any board committees.
- Compensation follows the standard Non-Employee Director Compensation Policy.
Financial Impact
No financial figures disclosed; standard director compensation per existing policy.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000031 |
| Document: abcellera-appointsxdrxxv.htm | 0001703057-26-000031 |
| Document: 0001703057-26-000031-index-headers.html | 0001703057-26-000031 |
| Document: 0001703057-26-000031-index.html | 0001703057-26-000031 |
| Document: 0001703057-26-000031.txt | 0001703057-26-000031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
8-K
| $5.80 awaiting T+5 | awaiting T+5 | — | $5.24 (−9.58%) |
|
May 11, 2026
4w ago
|
8-K
| $4.95 $4.16 | ▼ −15.96% | ▼ −16.04% | $5.24 (+5.86%) |
|
Apr 21, 2026
7w ago
|
ANALYST-DOWNGRADE
| $3.99 $4.16 | ▼ −4.26% | ▼ −3.18% | $5.24 (−31.33%) |
|
Feb 27, 2026
15w ago
|
Insider Cluster
| $3.61 $3.45 | ▼ −4.43% | ▼ −2.45% | $5.24 (+45.15%) |
|
Feb 24, 2026
15w ago
|
8-K
| $3.19 $3.63 | ▲ +13.79% | ▲ +14.89% | $5.24 (+64.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access